Umeclidinium Bromide and Vilanterol Trifenatate
Brand Names: Anoro Ellipta, Umeclidinium and Vilanterol Ellipta
Methodology & AI Transparency ⓘ
Umeclidinium Bromide and Vilanterol Trifenatate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage anoro ellipta: is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
- 2 Real-world patient consensus: 77% patient "Worth It" rating across 18 anonymous logs for Umeclidinium Bromide and Vilanterol Trifenatate (RxNorm 1487519).
- 3 Typical cash cost range: Dispensing cost comparison spans $185.00 mail/discount cash up to $453.25 uninsured retail (federal NADAC $7.7960).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Umeclidinium Bromide and Vilanterol Trifenatate include diarrhea (7.5%), constipation (4.7%), nausea (7.7%).
Ask our AI Specialists anything about Umeclidinium Bromide and Vilanterol Trifenatate
Umeclidinium Bromide and Vilanterol Trifenatate Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage anoro ellipta: is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use ANORO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma. The safety and effectiveness of ANORO ELLIPTA in asthma have not been established. ANORO ELLIPTA is a combination of umeclidinium, an anticholinergic, and vilanterol, a long-acting beta 2 -adrenergic agonist (LABA), indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
12.1 Mechanism of Action Anoro ellipta anoro ellipta: contains both umeclidinium and vilanterol. The mechanisms of action described below for the individual components apply to ANORO ELLIPTA. These drugs represent 2 different classes of medications (an anticholinergic and a LABA) each having different effects on clinical and physiological indices. Umeclidinium Umeclidinium is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5.
Following administration (62.5 ug/1 / 25 ug/1 Powder), Umeclidinium Bromide and Vilanterol Trifenatate achieves Estimated 62%–74% oral systemic absorption for Umeclidinium Bromide and Vilanterol Trifenatate bioavailability and peak plasma concentration (tmax) reached 1–4 hours post-dose for umeclidinium bromide and vilanterol trifenatate onset, governed by a Approximately 6–13 hours terminal plasma half-life for Umeclidinium Bromide and Vilanterol Trifenatate terminal half-life through phase i/ii hepatic conjugation of umeclidinium bromide and vilanterol trifenatate coupled with glomerular and tubular renal excretion.
Before initiating Umeclidinium Bromide and Vilanterol Trifenatate at 62.5 ug/1 / 25 ug/1 Powder, clinical safety checklists rule out 4 contraindications anoro ellipta: is contraindicated in:; patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to umeclidinium, vilanterol, or any of the excipients .. Logged tolerability patterns center on headache (7.8% of reports), nausea (7.7% of reports), diarrhea (7.5% of reports).
Combining Umeclidinium Bromide and Vilanterol Trifenatate with MAOIs within a 14-day washout window risks severe serotonergic or pressor toxicity.
Strong CYP3A4 blockade slows first-pass metabolism of Umeclidinium Bromide and Vilanterol Trifenatate, elevating systemic AUC exposure.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 Contraindications anoro ellipta: is contraindicated in:
- patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to umeclidinium, vilanterol, or any of the excipients .
Logged Side-Effect Incidence (18 Reports)
Umeclidinium Bromide and Vilanterol Trifenatate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Umeclidinium Bromide and Vilanterol Trifenatate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Population how the body absorbs the medicine Modeling of Fluticasone Furoate, Only marginal covariate effects were observed, and thus no dose adjustments are deemed necessary for FF, UMEC, or. Clinical pharmacokinetics • 2021-07-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33598874 ↗ |
Umeclidinium Bromide and Vilanterol Trifenatate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $7.7960/unit (~$233.88/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
| Virtual Psychiatric Medication Management (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $39.00 consult | Program details |
Umeclidinium Bromide and Vilanterol Trifenatate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Umeclidinium Bromide and Vilanterol Trifenatate RxNorm Concept ID | 1487519 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $7.7960 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 77.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Umeclidinium Bromide and Vilanterol Trifenatate Patient Community, Cohort Filters & Dosage Logs
Deterministic Umeclidinium Bromide and Vilanterol Trifenatate reference combining NIH RxNorm (1487519), Medicaid NADAC ($7.7960/unit), and anonymous cohort outcomes (77% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Umeclidinium Bromide and Vilanterol Trifenatate community threads and patient logs by age, biological sex, dosage, and treatment duration.